This IDE expansion represents a significant advancement in Adagio's clinical development pathway, enhancing the potential of its ULTA platform to become a standard-of-care solution for VT ablation. Traders should monitor enrollment progress and future clinical data readouts, which could catalyze valuation re-rating given the company's small market cap of $26M and high unmet need in the VT market.
Price Chart
Executive Summary
Adagio Medical received FDA Investigational Device Exemption (IDE) approval to expand its FULCRUM-VT trial to evaluate the safety and effectiveness of its next-generation vCLAS Ultra-Low Temperature Ablation (ULTA) Ventricular Ablation System for treating Sustained Monomorphic Ventricular Tachycardia (SMVT). The approval allows initiation of a clinical sub-study involving 55 patients to assess improvements in catheter maneuverability, shorter freeze times, and overall procedural efficiency.
Key Facts
- FDA granted IDE approval to expand the FULCRUM-VT trial to evaluate the next-generation vCLAS Ultra catheter
- The sub-study will enroll up to 55 patients in a staged design to assess safety and efficacy
- The vCLAS Ultra catheter achieves ablation temperatures of approximately -170°C, enabling single-freeze applications with over 50% reduction in ablation time in pre-clinical models
- The device is designed to improve energy delivery, navigation, lesion control, and procedural workflow efficiency
- The technology is intended to treat scar-mediated SMVT in both ischemic and non-ischemic patients through an endocardial approach
Financial Impact
No direct financial impact disclosed; the event is a regulatory milestone that de-risks future commercialization and supports potential market expansion for the vCLAS platform
Risk Factors
- Clinical trial may encounter delays or fail to demonstrate expected safety or efficacy
- Future regulatory approval is not guaranteed despite IDE clearance
- Company's small market cap and emerging growth status increase stock volatility risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-040673 |
| Document: tm2611362d1_ex99-1.htm | 0001104659-26-040673 |
| Document: 0001104659-26-040673-index-headers.html | 0001104659-26-040673 |
| Document: 0001104659-26-040673-index.html | 0001104659-26-040673 |
| Document: 0001104659-26-040673.txt | 0001104659-26-040673 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | DEF 14A | $0.1253 $0.1208 | ▼ −3.59% | ▼ −2.44% | $0.1030 (−17.80%) |
Oct 1, 2026 25d ago | 8-K | $0.1531 $0.1300 | ▲ +15.09% | ▲ +16.25% | $0.1030 (+32.72%) |
Sep 23, 2026 4w ago | 8-K | $0.2280 $0.1530 | ▲ +32.89% | ▲ +32.22% | $0.1030 (+54.82%) |
Aug 11, 2026 10w ago | 8-K | $0.7190 $0.6460 | ▲ +10.15% | ▲ +9.75% | $0.1030 (+85.67%) |
Jul 13, 2026 15w ago | 10-K/A | $0.5710 $0.5300 | ▼ −7.18% | ▼ −6.40% | $0.1030 (−81.96%) |
May 21, 2026 22w ago | 8-K | $0.8410 $0.7699 | ▼ −8.45% | ▼ −10.13% | $0.1030 (−87.75%) |
May 12, 2026 23w ago | 8-K | $0.9230 $0.8830 | ▼ −4.33% | ▼ −4.41% | $0.1030 (−88.84%) |
Apr 27, 2026 26w ago | 8-K | $1.15 $0.9410 | ▼ −18.17% | ▼ −18.57% | $0.1030 (−91.04%) |
Apr 8, 2026 28w ago | 8-K | $1.41 $1.43 | ▲ +1.42% | ▼ −2.10% | $0.1030 (−92.70%) |
Apr 6, 2026 29w ago | EFFECT | $1.25 $1.33 | ▼ −6.40% | ▼ −2.27% | $0.1030 (+91.76%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers